Menu
Search
|

Menu

Close
X

Innovate Biopharmaceuticals Inc INNT.OQ (NASDAQ Stock Exchange Capital Market)

5.30 USD
-- (--)
As of Feb 21
chart
Previous Close 5.30
Open --
Volume --
3m Avg Volume 4,847
Today’s High --
Today’s Low --
52 Week High 23.50
52 Week Low 3.43
Shares Outstanding (mil) 14.36
Market Capitalization (mil) 76.11
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
1
FY16
4
FY15
8
EPS (USD)
FY17
-0.635
FY16
-0.811
FY15
-1.084
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.75
Price to Sales (TTM)
vs sector
32.50
8.23
Price to Book (MRQ)
vs sector
--
5.26
Price to Cash Flow (TTM)
vs sector
--
26.16
Total Debt to Equity (MRQ)
vs sector
--
15.44
LT Debt to Equity (MRQ)
vs sector
--
12.05
Return on Investment (TTM)
vs sector
-850.83
13.63
Return on Equity (TTM)
vs sector
-850.83
15.25

EXECUTIVE LEADERSHIP

Sandeep Laumas
Executive Chairman of the Board, Since 2018
Salary: --
Bonus: --
Jay Madan
President, Director, Since 2018
Salary: --
Bonus: --
Christopher Prior
Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Lorin Johnson
Independent Director, Since 2018
Salary: --
Bonus: --
Anna Kazanchyan
Independent Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

8480 Honeycutt Rd Ste 120
RALEIGH   NC   27615-2261

Phone: +1919.2751933
Site:

Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and INN-329 (Secretin). The Company’s INN-108 is a novel small molecule comprised of two active parts with anti- inflammatory and immunodulatory properties coupled through an azo bond. The Company is developing INN-108 as a therapeutic for Ulcerative Colitis (UC). Its Secretin stimulated magnetic resonance cholangiopancreatography (MRCP) is a ionizing, radiation-free assessment of the pancreaticobiliary system. The Company has completed a phase II b clinical trial for celiac disease for INN-202. It is developing INN-108 in a phase II trial for inflammatory bowel disorders, mild to moderate UC and a Gastrointestinal (GI) orphan disease.

SPONSORED STORIES